Display options
Cite
Targeted Drugs Fall Short in Squamous Lung Cancer. Cancer Discov. 2020;11(1):OF3doi: 10.1158/2159-8290.CD-NB2020-107.
(2021). Targeted Drugs Fall Short in Squamous Lung Cancer. Cancer discovery, 11(1), OF3. https://doi.org/10.1158/2159-8290.CD-NB2020-107
"Targeted Drugs Fall Short in Squamous Lung Cancer." Cancer discovery vol. 11,1 (2021): OF3. doi: https://doi.org/10.1158/2159-8290.CD-NB2020-107
Targeted Drugs Fall Short in Squamous Lung Cancer. Cancer Discov. 2021 Jan;11(1):OF3. doi: 10.1158/2159-8290.CD-NB2020-107. Epub 2020 Nov 20. PMID: 33218972.
Copy Download .nbib Format: NLM
Share it on

Cancer Discov. 2021 Jan;11(1):OF3. doi: 10.1158/2159-8290.CD-NB2020-107. Epub 2020 Nov 20.

Targeted Drugs Fall Short in Squamous Lung Cancer.

Cancer discovery

[No authors listed]

PMID: 33218972 DOI: 10.1158/2159-8290.CD-NB2020-107

Abstract

A massive 5 year-plus effort to find molecularly targeted therapies for patients with recurrent, advanced-stage squamous cell carcinoma of the lungs has demonstrated the feasibility of rapidly screening tumors for rare genomic alterations and assigning drug treatments accordingly. Yet, the Lung Cancer Master Protocol study has yet to identify a broadly effective targeted agent for patients with biomarker-defined subtypes of the disease.

©2020 American Association for Cancer Research.

Publication Types